Abstract
A combination of doxorubicin ('Adriamycin') and B.C.N.U. (1,3 di[2-chloroethyl]-1-nitrosourea) (30 mg/m2 of each drug intravenously every 3-4 weeks) was used to treat thirteen multiple-myeloma patients who did not respond or were in relapse after remission produced by alkylating-agent/ prednisone therapy. All cases were staged according to total-body myeloma-cell number and followed quantitatively for response to therapy. Seven of the thirteen patients responded (54%). Two had complete clinical remissions and a greater than 75% reduction in tumour-cell mass lasting 12 and 16 months. Five others had partial remissions with lesser degrees of tumour-mass reduction and bone pain and improved hæmoglobin and serum-albumin concentrations. Toxicity was limited to occasional myelo-suppression, mild alopecia, and nausea. The results indicate the usefulness of doxorubicin/B.C.N.U. for myeloma patients who have relapsed during previously effective alkylating-agent therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 926-928 |
| Number of pages | 3 |
| Journal | The Lancet |
| Volume | 307 |
| Issue number | 7966 |
| DOIs | |
| State | Published - May 1 1976 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSE. / Alberts, David S; Durie, B. G M; Salmon, S. E.
In: The Lancet, Vol. 307, No. 7966, 01.05.1976, p. 926-928.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSE
AU - Alberts, David S
AU - Durie, B. G M
AU - Salmon, S. E.
PY - 1976/5/1
Y1 - 1976/5/1
N2 - A combination of doxorubicin ('Adriamycin') and B.C.N.U. (1,3 di[2-chloroethyl]-1-nitrosourea) (30 mg/m2 of each drug intravenously every 3-4 weeks) was used to treat thirteen multiple-myeloma patients who did not respond or were in relapse after remission produced by alkylating-agent/ prednisone therapy. All cases were staged according to total-body myeloma-cell number and followed quantitatively for response to therapy. Seven of the thirteen patients responded (54%). Two had complete clinical remissions and a greater than 75% reduction in tumour-cell mass lasting 12 and 16 months. Five others had partial remissions with lesser degrees of tumour-mass reduction and bone pain and improved hæmoglobin and serum-albumin concentrations. Toxicity was limited to occasional myelo-suppression, mild alopecia, and nausea. The results indicate the usefulness of doxorubicin/B.C.N.U. for myeloma patients who have relapsed during previously effective alkylating-agent therapy.
AB - A combination of doxorubicin ('Adriamycin') and B.C.N.U. (1,3 di[2-chloroethyl]-1-nitrosourea) (30 mg/m2 of each drug intravenously every 3-4 weeks) was used to treat thirteen multiple-myeloma patients who did not respond or were in relapse after remission produced by alkylating-agent/ prednisone therapy. All cases were staged according to total-body myeloma-cell number and followed quantitatively for response to therapy. Seven of the thirteen patients responded (54%). Two had complete clinical remissions and a greater than 75% reduction in tumour-cell mass lasting 12 and 16 months. Five others had partial remissions with lesser degrees of tumour-mass reduction and bone pain and improved hæmoglobin and serum-albumin concentrations. Toxicity was limited to occasional myelo-suppression, mild alopecia, and nausea. The results indicate the usefulness of doxorubicin/B.C.N.U. for myeloma patients who have relapsed during previously effective alkylating-agent therapy.
UR - http://www.scopus.com/inward/record.url?scp=0017273268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017273268&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(76)92710-0
DO - 10.1016/S0140-6736(76)92710-0
M3 - Article
C2 - 57335
AN - SCOPUS:0017273268
VL - 307
SP - 926
EP - 928
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 7966
ER -